Technical Analysis for FOLD - Amicus Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
B | 11.69 | -0.60% | -0.07 |
Earnings due: Nov 6
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Golden Cross | Bullish | 0.00% | |
Calm After Storm | Range Contraction | 0.00% | |
NR7 | Range Contraction | 0.00% | |
180 Bullish Setup | Bullish Swing Setup | -0.60% | |
Inside Day | Range Contraction | -0.60% | |
Upper Bollinger Band Walk | Strength | 2.54% | |
Gapped Down | Weakness | 2.54% | |
Calm After Storm | Range Contraction | -1.52% | |
Upper Bollinger Band Walk | Strength | -1.52% | |
Inside Day | Range Contraction | -1.52% |
Alert | Time |
---|---|
Possible NR7 | 2 days ago |
Down 1% | 2 days ago |
Bullish 180 Entry | 2 days ago |
Rose Above Previous Day's High | 2 days ago |
Up 3% | 3 days ago |
Get a Trading Assistant
- Earnings date: 11/06/2024
Amicus Therapeutics, Inc. Description
Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs known as pharmacological chaperones. It develops pharmacological chaperones as next-generation medicines for a range of rare and orphan diseases with a focus on improved therapies for lysosomal storage disorders. The company's development programs include small molecules as monotherapy treatments for Fabry and other lysosomal storage diseases, and enzyme replacement therapy (ERT). Its chaperone-advanced replacement therapy programs comprise chaperones co-administered with currently marketed ERTs, as well as proprietary therapeutic enzymes co-formulated with pharmacological chaperones as next-generation ERTs. The company's primary product includes migalastat HCl, a product candidate for Fabry disease that is in Phase III global registration studies for patients with genetic mutations. Its products also comprise AT2220, which has completed Phase II safety used for the treatment of Pompe disease; and AT3375 and afegostat tartrate that are in preclinical studies used for treating Gaucher disease. The company has strategic collaboration with GlaxoSmithKline PLC to develop and commercialize migalastat HCl. Amicus Therapeutics, Inc. was founded in 2002 and is based in Cranbury, New Jersey.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Rare Diseases Enzymes Orphan Drug Lipid Storage Disorders Inborn Errors Of Metabolism Enzyme Replacement Therapy Fabry Disease Lysosomal Storage Disorder Orphan Disease Pompe Disease Gaucher Disease Lysosomal Storage Disorders Rare And Orphan Diseases Treatment Of Pompe Disease
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 14.57 |
52 Week Low | 9.02 |
Average Volume | 2,303,866 |
200-Day Moving Average | 11.18 |
50-Day Moving Average | 11.19 |
20-Day Moving Average | 10.89 |
10-Day Moving Average | 11.38 |
Average True Range | 0.40 |
RSI (14) | 59.35 |
ADX | 31.4 |
+DI | 28.87 |
-DI | 18.95 |
Chandelier Exit (Long, 3 ATRs) | 11.17 |
Chandelier Exit (Short, 3 ATRs) | 11.11 |
Upper Bollinger Bands | 12.29 |
Lower Bollinger Band | 9.50 |
Percent B (%b) | 0.79 |
BandWidth | 25.58 |
MACD Line | 0.22 |
MACD Signal Line | 0.08 |
MACD Histogram | 0.1451 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 12.04 | ||||
Resistance 3 (R3) | 12.06 | 11.96 | 11.98 | ||
Resistance 2 (R2) | 11.96 | 11.87 | 11.95 | 11.96 | |
Resistance 1 (R1) | 11.82 | 11.82 | 11.78 | 11.81 | 11.94 |
Pivot Point | 11.73 | 11.73 | 11.70 | 11.72 | 11.73 |
Support 1 (S1) | 11.59 | 11.64 | 11.54 | 11.57 | 11.44 |
Support 2 (S2) | 11.50 | 11.58 | 11.49 | 11.42 | |
Support 3 (S3) | 11.36 | 11.50 | 11.40 | ||
Support 4 (S4) | 11.34 |